Bispecific Antibodies for Cancer Market by Type, Distribution Channel. and Geography - Forecast and Analysis 2023-2027

Bispecific Antibodies for Cancer Market Forecast 2023-2027

The Global Bispecific Antibodies for Cancer Market is estimated to increase by USD 400.72 million and grow at a CAGR of 8.82% between 2022 and 2027. The growth of the market depends on several factors, including the increasing prevalence of cancer, the advantages of bispecific antibodies over monoclonal antibodies, and a strong pipeline. The market for cancer treatments is witnessing strong growth, fueled by the rising incidence of cancer worldwide. Cancer, which causes substantial economic burdens and premature fatalities, has spurred significant investments in research and development from governmental bodies, research institutes, and pharmaceutical firms. This increased investment, particularly in oncology research, is fueling the demand for bispecific antibodies as a promising therapy. Moreover, the growing healthcare spending in developing countries is expected to additionally boost market expansion.

What will be the size of the Bispecific Antibodies For Cancer Market During the Forecast Period?

To learn more about this report, Download Report Sample

Market Segmentation

This report extensively covers market segmentation by type (CD19 or SC3 and CD30 or CD16A), distribution channel (hospitals, retail pharmacies, and online), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

By Type

The market share growth of the CD19 or CD3 segment will be significant during the forecast period. The increase in the prevalence of acute lymphocytic leukemia drives the growth of the segment. Acute lymphoblastic leukemia is most common in children, adolescents, and young adults. The American Cancer Society estimated in the US, the number of new cases of acute lymphocytic leukemia (ALL) was 6,660 in 2022. Due to the increase in the prevalence of acute lymphoblastic leukemia, the demand for novel drugs to treat this cancer has increased.

Get a glance at the market contribution of various segments Request a PDF Sample

The CD19 or CD3 segment was valued at USD 371.81 million in 2017 and continued to grow until 2021. Blinatumomab, a CD19/CD3 bispecific antibody (bsAb) is designed in the BiTEs format. Treatment with BLINCYTO leads to the depletion of B lymphocytes and precursors in peripheral blood, which is slowly restored after the end of treatment. BLINCYTO is approved in 57 countries, including the US, all the member countries of the EU and the European Economic Area, Canada, and Australia. Also, the Centers for Medicare and Medicaid Services provides add-on payment for BLINCYTO inpatient therapy in the US. Therefore, the availability of reimbursement schemes and coverage by health insurance plans will also drive market growth during the forecast period.

Key Regions

For more insights on the market share of various regions Request PDF Sample now!

North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The market in North America is led by the US and is driven by the growing prevalence of cancer, a strong presence of vendors such as Amgen and Johnson and Johnson Services, Inc., and the availability of reimbursement schemes. Cancer is one of the most common chronic diseases in the US. Also, in every 100,000 population, 436 new cancer cases were reported, and about 156 died of cancer in the country every year. Cancers such as breast cancer, colon and rectum cancer, prostate cancer, tracheal, bronchus, and lung cancer are the most common cancers prevalent in the US. The risk of a person developing ALL cancer is approximately less than 1% of the overall cancer rate in the US. Therefore, the increase in the prevalence of ALL cancer is encouraging researchers to develop first-in-class novel therapeutics such as bispecific antibodies.

Market Dynamics and Customer Landscape

Bispecific Antibodies for Cancer hold immense promise in revolutionizing cancer treatment, driven by advancements in targeted therapies and antibody engineering technologies. Organizations like the National Association of Chronic Disease Directors and the Centers for Disease Control and Prevention recognize their potential in combating cancer, a leading cause of mortality among adult Americans. With the bispecific antibodies market witnessing substantial growth, fueled by FDA approvals and clinical trials targeting multiple myeloma and other malignancies, the landscape of cancer therapy is rapidly evolving. However, challenges such as supply chain disruptions and diverted resources persist, highlighting the need for continued investment in research and development. Exciting developments like Tibulizumab and Ozoralizumab underscore the ongoing technological advancements in this field, promising new avenues in personalized cancer treatment. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

The market for the market is experiencing robust growth, propelled by the increasing prevalence of cancer globally. Cancer, responsible for significant economic losses and premature deaths, has prompted substantial investments in research and development by governmental organizations, research institutions, and pharmaceutical companies. This surge in investment, particularly in the oncology segment, is driving the demand for bispecific antibodies as a promising treatment option. Additionally, the escalating healthcare expenditure in developing nations is poised to further augment market growth. As the demand for supportive care therapy drugs rises alongside the increasing prevalence of cancer, the market for bispecific antibodies is expected to thrive, offering innovative solutions for combating this widespread disease.

Significant Market Trends

Increase in strategic alliances is the key trend in the market. Opportunities for multiple start-up businesses to enter the market as well as for strategic alliances by medium enterprises and conglomerate companies are being created by the growing demand for bispecific antibodies for treating various types of cancer. For instance, in 2021, Lilly and Merus NV collaborated to discover novel T-Cell Re-Directing bispecific antibodies. According to the terms of the partnership, Loxo Oncology at Lilly will oversee additional research, development, and commercialization operations, while Merus will be in charge of discovery and early-stage research activities.

Similarly, in 2021, Xencor and MD Anderson announced a collaboration to develop novel T Cell-Engaging bispecific antibodies for the treatment of cancer patients. Thus, increasing collaborations will drive the discovery of bispecific antibodies during the forecast period.

Major Market Challenge

The high cost of drugs is the major challenge impeding the market growth. The majority of cancer patients in low- and middle-income countries leave the course of drug therapy in between as these drugs are priced beyond their reach. Patients with a history of cancer were more likely to stop their treatment due to the high cost of drugs used in the treatment of various cancers, such as KEYTRUDA from Merck, which is used to treat non-small cell lung cancer and can cost USD 107,520.00 (84,000 Euros) per patient.

Cancer treatment success depends on the patient's adherence to the full course of therapy, including chemotherapy, targeted therapy, and immunotherapy, all of which involve the use of drugs. Therefore, the high cost of drugs will pose a challenge to the growth of the market during the forecast period.

Key Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Who are the Major Bispecific Antibodies for Cancer Market Companies?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Glenmark Pharmaceuticals Ltd. - The company offers bispecific antibody solutions for cancer such as CD38XCD3.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market players, including:

• Aptevo Therapeutics Inc.
• Astellas Pharma Inc.
• Chugai Pharmaceutical Co. Ltd.
• Eli Lilly and Co.
• EPIMAB BIOTHERAPEUTICS INC.
• F STAR THERAPEUTICS INC.
• F. Hoffmann La Roche Ltd.
• Johnson and Johnson
• Mereo BioPharma Group Plc
• Merus N.V.
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• TG Therapeutics Inc.
• Xencor Inc.
• Y mAbs Therapeutics Inc.

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Segment Overview

The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

• Type Outlook 
  • CD19 or CD3
  • CD30 or CD16A

• Distribution Channel Outlook
  • Hospitals
  • Retail pharmacies
  • Online

• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Brazil
    • Argentina

Market Analyst Overview

The Market is witnessing remarkable advancements in targeted therapies, particularly in the treatment of multiple myeloma and other cancer segments. As autoimmune disorders and infectious diseases continue to pose significant health challenges, the development of biological therapies like bispecific antibodies holds immense promise. With advancements in antibody engineering technologies and precision medicine, there's a surge in interest and confidence in bispecific antibodies targeting B-cell maturation antigen, crucial for relapsed or refractory multiple myeloma. This has spurred accelerated research and development activities, supported by high investments from pharmaceutical giants like Genentech.

Regulatory bodies such as the FDA and WHO are actively involved in shaping the regulatory environment to facilitate the development and approval of bispecific antibodies. Despite supply chain challenges and strained healthcare systems, the market for bispecific antibodies is poised for substantial growth, driven by complementary expertise, technological advancements, and a shared commitment to combat cancer and improve patient outcomes.

The Bispecific Antibodies for Cancer Market is witnessing significant growth due to targeted therapies, particularly in the cancer segment. As healthcare expenditure soars to USD8 trillion, organizations like the National Association of Chronic Disease Directors and the Centers for Disease Control and Prevention emphasize the importance of personalized medicine. Bispecific antibodies, such as tibulizumab and ozoralizumab, are at the forefront of clinical trials, offering promising developments in treating various cancers, including lymphoma. With a focus on inflammatory and autoimmune disorders like rheumatoid arthritis, psoriasis, Crohn's disease, and multiple sclerosis, the market sees high investment in R&D, driving advancements in bispecific antibody technology. As the Global Bispecific Antibodies Market expands, diverted resources are redirected to combat mental health disorders, ensuring comprehensive healthcare solutions for adult Americans.

Bispecific Antibodies For Cancer Market Scope
Report Coverage	Details
Page number	155
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 8.82%
Market growth 2023-2027	USD 400.72 million
Market structure	Fragmented
YoY growth 2022-2023(%)	6.2
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 38%
Key countries	US, Ireland, Hungary, China, and India
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	ABL Bio Inc., AFFIMED N.V., Akeso Inc., Amgen Inc., Aptevo Therapeutics Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly and Co., EPIMAB BIOTHERAPEUTICS INC., F STAR THERAPEUTICS INC., F. Hoffmann La Roche Ltd., Glenmark Pharmaceuticals Ltd., Johnson and Johnson, Mereo BioPharma Group Plc, Merus N.V., Pfizer Inc., Regeneron Pharmaceuticals Inc., TG Therapeutics Inc., Xencor Inc., and Y mAbs Therapeutics Inc.
Market dynamics	Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our market research report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Market Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about vendors
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this report to meet your requirements. Get in touch